WEIGHT LOSS TREATMENTS

Mounjaro targets both the GLP-1 and GIP receptors, meaning that as well as slowing stomach emptying and increasing fullness and satiety, it plays an additional role in enhancing the body's ability to use stored fat as energy, and potentially providing broader weight management effects.

• Mounjaro is taken as a once-weekly, dose-set pen injection.

A trial with 2539 adults found that weekly tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks achieved significant weight loss in overweight and obese patients, with a higher percentage achieving 5%, 10%, 15%, and 20% or more weight loss compared to placebo.¹

Always read the label and store as instructed.

• Nausea

• Diarrhoea

• Vomiting

• Pancreatitis (rarely)

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

Wegovy, brand name for semaglutide, is approved for weight loss. Semaglutide works by targeting the GLP-1 receptor, slowing stomach emptying, increasing fullness, and reducing cravings. Semaglutide has been shown to reduce certain cardiovascular events by up to 20%.⁶

• Semaglutide is taken as a once-weekly, dose-set pen injection.

In a study with 1961 adults, semaglutide (2.4 mg) over 68 weeks resulted in a 15% weight reduction, with 86% of adults achieving significant weight loss.⁷

Always read the label and store as instructed.

• Nausea

• Diarrhoea

• Vomiting

• Pancreatitis (rarely)

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

The active ingredient in Alli, orlistat, works by decreasing the amount of dietary fat your body can absorb by blocking the action of lipase, the enzyme responsible for breaking down fats to be absorbed by the intestines. This means that around a quarter of the fat you eat while taking Alli won’t be broken down, and is instead passed through the body.

• Taken as an oral capsule, three times per day with fat-containing meals.

In the 4-year XENDOS trial, 60% of patients on orlistat and 35% on placebo lost at least 5% of their baseline body weight after 12 weeks. Of these, 62% of orlistat patients and 52% of placebo patients lost ≥ 10% of their baseline weight after one year. Only 5% of orlistat and 4% of placebo patients who did not lose 5% initially reached a 10% weight loss after one year.⁹

• It’s recommended that you keep your fat intake to no more than 30% of your total calories, or about 15 grams of fat per meal

• Side effects can be unpleasant

• Frequent bowel movements

• Faecal incontinence

• Abdominal pain

• Diarrhoea

  *If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.